1. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds
- Author
-
Carmen Gil, Pablo D. Dans, Ana Martínez, F. Javier Luque, Santiago Conde, Concepción Pérez, Valle Palomo, Daniel I. Perez, Instituto de Quimica Médica (CSIC), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Institut Pasteur de Montevideo, Réseau International des Instituts Pasteur (RIIP), Departamento de Fisicoquímica e Instituto de Biomedicina, Facultad de farmacia-Universidad de Barcelona, and Financial support from MICINN and ISCiii (projects nos. SAF2009-13015-CO2-01, SAF2008-05595, SAF2006-01249 and RD07-0060/0015) and computational facilities from the CESCA are also acknowledged. D. I. P. acknowledges a postdoctoral grant to the CSIC (JAEDoc program) and V. P. a predoctoral grant (JAEPre program).
- Subjects
Models, Molecular ,MESH: Neurons ,Plasma protein binding ,MESH: Ketones ,Pharmacology ,MESH: Drug Design ,01 natural sciences ,MESH: Receptors, Neurotransmitter ,MESH: Neurodegenerative Diseases ,Glycogen Synthase Kinase 3 ,Mice ,Adenosine Triphosphate ,MESH: Structure-Activity Relationship ,GSK-3 ,Cerebellum ,Drug Discovery ,MESH: Adenosine Triphosphate ,MESH: Animals ,Phosphorylation ,Receptor ,MESH: Glycogen Synthase Kinase 3 ,Neurons ,0303 health sciences ,Chemistry ,Neurodegenerative Diseases ,Stereoisomerism ,Ketones ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,Receptors, Neurotransmitter ,3. Good health ,MESH: tau Proteins ,MESH: Cattle ,medicine.anatomical_structure ,Biochemistry ,Molecular Medicine ,Signal transduction ,MESH: Models, Molecular ,Protein Binding ,MESH: Rats ,Central nervous system ,tau Proteins ,In Vitro Techniques ,Structure-Activity Relationship ,03 medical and health sciences ,medicine ,Animals ,Humans ,Structure–activity relationship ,MESH: Protein Binding ,Binding site ,MESH: Mice ,030304 developmental biology ,Binding Sites ,MESH: Humans ,MESH: Phosphorylation ,010405 organic chemistry ,MESH: Central Nervous System Agents ,MESH: Stereoisomerism ,MESH: Cerebellum ,Rats ,0104 chemical sciences ,MESH: Binding Sites ,Drug Design ,Cattle ,[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM] ,Central Nervous System Agents - Abstract
Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, being one of the inhibitors on clinical trials for different tauopathies. Following our hypothesis based on the enhanced reactivity of residue Cys199 in the binding site of GSK-3, we examine here the suitability of phenylhalomethylketones as irreversible inhibitors. Our data confirm that the halomethylketone unit is essential for the inhibitory activity. Moreover, addition of the halomethylketone moiety to reversible inhibitors turned them into irreversible inhibitors with IC50 values in the nanomolar range. Overall, the results point out that these compounds might be useful pharmacological tools to explore physiological and pathological processes related to signaling pathways regulated by GSK-3 opening new avenues for the discovery of novel GSK-3 inhibitors. © 2011 American Chemical Society.
- Published
- 2011
- Full Text
- View/download PDF